About This Publication

What this site is

BPC157clinic.com is a research-summary publication covering the preclinical and clinical literature on BPC-157 — also catalogued as Pentadecapeptide BPC 157, PL 14736, PL-10, and PLD-116. The site exists to make a thirty-year, single-lab-dominated, predominantly rodent literature legible to a reader who wants to know what was actually studied, at what dose, in what species, with what reported outcome.

The word clinic in the domain refers to clinical research — the published bench-and-pilot record — not to patient services. No medical care is provided through this site. No product is sold. No protocol is recommended. No affiliate or referral relationship exists between this site and any vendor of peptides, research chemicals, supplements, or compounded preparations.

Editorial standards

Standards. Three rules govern what appears on this site:

First, every quantitative claim — every dose, every concentration, every percentage, every half-life — is anchored to a citation listed on the references page. Citations are to peer-reviewed journal articles indexed in PubMed, PMC, or the publisher's own DOI registry. Where a citation is to a review or commentary, the review is cited, not the underlying primary literature it summarizes.

Second, doses are reported in the species and route in which they were administered. A rat at 10 μg/kg intraperitoneal is described as such. The site does not perform allometric scaling. Where an author has proposed a human dose extrapolation (He et al., 2022), the proposal is reported as a single citation, not as guidance.

Third, no medical claim is made about any human indication. The peptide is not approved by the FDA, EMA, MHRA, TGA, or any other major regulatory authority. The FDA placed it in Category 2 in September 2023, but its nomination is now withdrawn, with the safety concerns retained; withdrawal means neither Category 1 status nor permission to compound. WADA still prohibits it under section S0 (effective 1 January 2022). The index and FAQ discuss these regulatory distinctions.

What this site is not

It is not a clinic. It is not a treatment provider. It is not a peptide vendor or a vendor's affiliate. It does not collect identifying patient information. It is not a substitute for advice from a licensed clinician. It does not endorse, recommend, or facilitate any human use of BPC-157.

Readers interested in conditions described in the rodent literature — tendon and ligament injury, gastrointestinal anastomotic healing, fistula closure, ischemia-reperfusion, traumatic brain injury, peripheral nerve injury, spinal cord injury — are referred to a licensed clinician operating within their jurisdiction, working with regulated, evidence-based interventions.

Disclaimer

BPC157clinic.com is a research-summary publication covering the BPC-157 literature. Nothing on this site constitutes medical advice, diagnosis, treatment recommendation, or an offer to sell any compound or preparation. BPC-157 is not approved by the FDA, EMA, or any other major regulatory authority for human use, and is prohibited under WADA section S0 for athletes subject to anti-doping rules. The site does not operate a clinic, dispense product, recommend doses, or refer to vendors. It does not collect identifying patient information.